BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen B, Gao X, Zhong J, Ren J, Zhu X, Liu Z, Wu K, Kalabic J, Yu Z, Huang B, Kwatra N, Doan T, Robinson AM, Chen MH. Efficacy and safety of adalimumab in Chinese patients with moderately to severely active Crohn's disease: results from a randomized trial. Therap Adv Gastroenterol 2020;13:1756284820938960. [PMID: 32733600 DOI: 10.1177/1756284820938960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2021;6:1002-14. [PMID: 34688373 DOI: 10.1016/S2468-1253(21)00312-5] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang YC, Feng YT, Lin YC, Lee CT, Tung TH. Effect of adalimumab interventions on general infection among adults: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti Infect Ther 2021;:1-17. [PMID: 33703989 DOI: 10.1080/14787210.2021.1902804] [Reference Citation Analysis]
3 Wu G, Yang Y, Liu M, Wang Y, Guo Q. Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease. Front Pharmacol 2021;12:655865. [PMID: 33935772 DOI: 10.3389/fphar.2021.655865] [Reference Citation Analysis]
4 Yu B, Zhao L, Jin S, He H, Zhang J, Wang X. Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease. Front Immunol 2022;13:828219. [DOI: 10.3389/fimmu.2022.828219] [Reference Citation Analysis]